Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product

This article was originally published in The Pink Sheet Daily

Executive Summary

Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.

You may also be interested in...



Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris

Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.

Financings Of The Fortnight: Could California’s Regenerative Medicine Ballot Initiative Pass Today?

Plus news on recent financings by bluebird bio, Puma Biotechnology, Atara Biotherapeutics and Aclaris Therapeutics.

Vicept Management, VCs Team Up Again To Launch Aclaris With $21M

Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel